Switch theme
Sign up to access all valuation multiples
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
1992
2.7K+
LTM Revenue $826M
LTM EBITDA $32.6M
$454M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Myriad Genetics has a last 12-month revenue (LTM) of $826M and a last 12-month EBITDA of $32.6M.
In the most recent fiscal year, Myriad Genetics achieved revenue of $838M and an EBITDA of -$59.5M.
Myriad Genetics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Myriad Genetics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $826M | XXX | $838M | XXX | XXX | XXX |
| Gross Profit | $577M | XXX | $585M | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $32.6M | XXX | -$59.5M | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | -7% | XXX | XXX | XXX |
| EBIT | $12.3M | XXX | -$88.0M | XXX | XXX | XXX |
| EBIT Margin | 1% | XXX | -11% | XXX | XXX | XXX |
| Net Profit | $6.9M | XXX | -$127M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | -15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Myriad Genetics's stock price is $4.
Myriad Genetics has current market cap of $388M, and EV of $454M.
See Myriad Genetics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $454M | $388M | XXX | XXX | XXX | XXX | $0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Myriad Genetics has market cap of $388M and EV of $454M.
Myriad Genetics's trades at 0.5x EV/Revenue multiple, and -7.6x EV/EBITDA.
Equity research analysts estimate Myriad Genetics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Myriad Genetics has a P/E ratio of 55.9x.
See valuation multiples for Myriad Genetics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $388M | XXX | $388M | XXX | XXX | XXX |
| EV (current) | $454M | XXX | $454M | XXX | XXX | XXX |
| EV/Revenue | 0.5x | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBITDA | 13.9x | XXX | -7.6x | XXX | XXX | XXX |
| EV/EBIT | 36.9x | XXX | -5.2x | XXX | XXX | XXX |
| EV/Gross Profit | 0.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 55.9x | XXX | -3.0x | XXX | XXX | XXX |
| EV/FCF | 16.7x | XXX | -11.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMyriad Genetics's last 12 month revenue growth is 1%
Myriad Genetics's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Myriad Genetics's rule of 40 is -25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Myriad Genetics's rule of X is 6% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Myriad Genetics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | -7% | XXX | XXX | XXX |
| EBITDA Growth | -7% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -25% | XXX | -6% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 6% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 80% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| ToolGen | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Myriad Genetics acquired XXX companies to date.
Last acquisition by Myriad Genetics was XXXXXXXX, XXXXX XXXXX XXXXXX . Myriad Genetics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Myriad Genetics founded? | Myriad Genetics was founded in 1992. |
| Where is Myriad Genetics headquartered? | Myriad Genetics is headquartered in United States of America. |
| How many employees does Myriad Genetics have? | As of today, Myriad Genetics has 2.7K+ employees. |
| Who is the CEO of Myriad Genetics? | Myriad Genetics's CEO is Mr. Samraat S. Raha. |
| Is Myriad Genetics publicy listed? | Yes, Myriad Genetics is a public company listed on NAS. |
| What is the stock symbol of Myriad Genetics? | Myriad Genetics trades under MYGN ticker. |
| When did Myriad Genetics go public? | Myriad Genetics went public in 1995. |
| Who are competitors of Myriad Genetics? | Similar companies to Myriad Genetics include e.g. EZZ Life Science, Epigenomics, ToolGen, 4basebio. |
| What is the current market cap of Myriad Genetics? | Myriad Genetics's current market cap is $388M |
| What is the current revenue of Myriad Genetics? | Myriad Genetics's last 12 months revenue is $826M. |
| What is the current revenue growth of Myriad Genetics? | Myriad Genetics revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Myriad Genetics? | Current revenue multiple of Myriad Genetics is 0.5x. |
| Is Myriad Genetics profitable? | Yes, Myriad Genetics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Myriad Genetics? | Myriad Genetics's last 12 months EBITDA is $32.6M. |
| What is Myriad Genetics's EBITDA margin? | Myriad Genetics's last 12 months EBITDA margin is 4%. |
| What is the current EV/EBITDA multiple of Myriad Genetics? | Current EBITDA multiple of Myriad Genetics is 13.9x. |
| What is the current FCF of Myriad Genetics? | Myriad Genetics's last 12 months FCF is $27.2M. |
| What is Myriad Genetics's FCF margin? | Myriad Genetics's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Myriad Genetics? | Current FCF multiple of Myriad Genetics is 16.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
